JP6950006B2 - ネクローシス阻害剤であるヘテロアリール化合物、それを用いる組成物及び方法 - Google Patents

ネクローシス阻害剤であるヘテロアリール化合物、それを用いる組成物及び方法 Download PDF

Info

Publication number
JP6950006B2
JP6950006B2 JP2019569828A JP2019569828A JP6950006B2 JP 6950006 B2 JP6950006 B2 JP 6950006B2 JP 2019569828 A JP2019569828 A JP 2019569828A JP 2019569828 A JP2019569828 A JP 2019569828A JP 6950006 B2 JP6950006 B2 JP 6950006B2
Authority
JP
Japan
Prior art keywords
mmol
mixture
alkyl
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019569828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525417A (ja
JP2020525417A5 (https=
Inventor
シャオフー ヂャン，
シャオフー ヂャン，
ハイクォ マー，
ハイクォ マー，
ジーユェ ヂォン，
ジーユェ ヂォン，
スーダン フー，
スーダン フー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2018/039180 external-priority patent/WO2018237370A1/en
Publication of JP2020525417A publication Critical patent/JP2020525417A/ja
Publication of JP2020525417A5 publication Critical patent/JP2020525417A5/ja
Application granted granted Critical
Publication of JP6950006B2 publication Critical patent/JP6950006B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2019569828A 2017-06-23 2018-06-23 ネクローシス阻害剤であるヘテロアリール化合物、それを用いる組成物及び方法 Active JP6950006B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710483983 2017-06-23
CN201710483983.2 2017-06-23
CN201810575869.7A CN109111464B (zh) 2017-06-23 2018-06-06 一种具有细胞坏死抑制活性的杂环化合物
CN201810575869.7 2018-06-06
PCT/US2018/039180 WO2018237370A1 (en) 2017-06-23 2018-06-23 Heteroaryl compounds as inhibitors of necrosis, composition and method using the same

Publications (3)

Publication Number Publication Date
JP2020525417A JP2020525417A (ja) 2020-08-27
JP2020525417A5 JP2020525417A5 (https=) 2021-07-26
JP6950006B2 true JP6950006B2 (ja) 2021-10-13

Family

ID=64821922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569828A Active JP6950006B2 (ja) 2017-06-23 2018-06-23 ネクローシス阻害剤であるヘテロアリール化合物、それを用いる組成物及び方法

Country Status (6)

Country Link
US (1) US11339177B2 (https=)
EP (1) EP3642193B1 (https=)
JP (1) JP6950006B2 (https=)
KR (1) KR102367257B1 (https=)
CN (1) CN109111464B (https=)
ES (1) ES2916549T3 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202116771A (zh) * 2019-07-17 2021-05-01 英屬開曼群島商百濟神州有限公司 作為ｈｐｋ１抑制劑之三環化合物及其用途
CN115894489A (zh) * 2021-09-22 2023-04-04 中国药科大学 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY155517A (en) * 2008-03-31 2015-10-30 C&C Res Lab Heterocyclic derivatives
WO2010008847A2 (en) * 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
WO2010100144A1 (en) * 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase
US9295673B2 (en) * 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US20160256458A1 (en) * 2013-11-18 2016-09-08 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
CN106029076B (zh) * 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
WO2018017435A1 (en) * 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
CN107641118B (zh) 2016-07-22 2020-11-06 爱科诺生物医药股份有限公司 具有细胞坏死抑制活性的化合物及其组合物和应用
RU2019133646A (ru) * 2017-03-30 2021-04-30 Ф. Хоффманн-Ля Рош Аг Изохинолины в качестве ингибиторов hpk1

Also Published As

Publication number Publication date
JP2020525417A (ja) 2020-08-27
EP3642193B1 (en) 2022-04-27
EP3642193A1 (en) 2020-04-29
US20210155635A1 (en) 2021-05-27
CN109111464A (zh) 2019-01-01
KR102367257B1 (ko) 2022-02-24
KR20200017411A (ko) 2020-02-18
CN109111464B (zh) 2021-02-26
ES2916549T3 (es) 2022-07-01
EP3642193A4 (en) 2021-03-10
US11339177B2 (en) 2022-05-24

Similar Documents

Publication Publication Date Title
WO2018237370A1 (en) Heteroaryl compounds as inhibitors of necrosis, composition and method using the same
JP2024514844A (ja) Ｍｙｔ１阻害剤を含む併用治療
EP2895488B1 (en) Tricyclic gyrase inhibitors for use as antibacterial agents
JP7410954B2 (ja) ネクローシス阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法
CN115557949A (zh) 四环类衍生物、其制备方法及其在医药上的应用
AU2016322848B2 (en) 1-phenylpyrrolidin-2-one derivatives as perk inhibitors
BR112020011746A2 (pt) compostos heterocíclicos bicíclicos substituídos atuando como inibidores de prmt5
CA2902781A1 (en) Novel pyrazole derivative
CN115515949A (zh) 新型氨基嘧啶类egfr抑制剂
JP7025359B2 (ja) ネクローシス阻害剤であるヘテロアリール化合物、その組成物及び用途
CA2829939A1 (en) Tricyclic gyrase inhibitors
KR20080075027A (ko) Ｆａｂｉ 억제제 및 항박테리아제로서의헤테로시클릴아크릴아미드 화합물
CA3152508A1 (en) Perk inhibiting pyrrolopyrimidine compounds
CA3119390A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
CN114437116A (zh) 杂环化合物及其制备方法、药物组合物和应用
CN117561058A (zh) Cdk2抑制剂及其使用方法
US20150306070A1 (en) Use of maleimide derivatives for preventing and treating leukemia
JP6950006B2 (ja) ネクローシス阻害剤であるヘテロアリール化合物、それを用いる組成物及び方法
KR20150021120A (ko) 헤테로아릴 화합물 및 이의 이용 방법
BR112021009309A2 (pt) compostos heteroaromáticos adicionais com atividade contra rsv
TW202214634A (zh) 雜環化合物及其衍生物
JP2024533433A (ja) Ｅｎｐｐ１阻害活性を有するヒドロキサム酸系化合物及びその使用
CA3114259C (en) Aminonorbornane derivative and manufacture method therefor and use thereof
WO2018052065A1 (ja) 複素環アミド化合物
WO2026027857A1 (en) N-cyanopyrrolidine deviratives having activity as inhibiotrs of ubiquitin specific peptidase 30

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210430

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210824

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210914

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210922

R150 Certificate of patent or registration of utility model

Ref document number: 6950006

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250